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Possible West Nile Virus Infection in Organ Transplant Recipients -  
Information for Clinicians
The Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Health 
Resources and Services Administration (HRSA), the Georgia State Division of Public Health, and the Florida 
Department of Health are investigating illnesses among four recipients of organ transplants from a single donor. 
West Nile virus infection was confirmed in the organ donor by detection of viral genomic material by PC R  in a 
serum sample obtained on the day of death. Because of injuries sustained during a motor vehicle accident, the 
donor had received numerous transfusions of blood products before death. West Nile virus infection has been 
confirmed in three of the organ recipients; the fourth recipient has not yet been tested. Additional clinical 
information about the recipients is indicated below.
Case 1 - A  female patient received a kidney transplant on August 3, 2002. Approximately two weeks after 
transplant, while at home, the patient developed fever, backache, non-bloody diarrhea, 4-5 days of rash, and 6 
days of non-specific upper respiratory symptoms. She was admitted to the hospital and over the next five days 
had progressive decline in mental status requiring mechanical ventilation. Serology for West Nile virus IgG 
performed at a commercial reference laboratory was reported as 1:16 by indirect fluorescent antibody (IFA); <1:16 
was considered negative. A  CSF sample obtained approximately two weeks after illness onset was positive for 
IgM antibody by MAC-ELISA at CDC. The patient's mental status is improving and she no longer requires 
ventilatory support.
Case 2 - A  male patient received a kidney transplant on August 2, 2002. Approximately two and a half weeks after 
transplant, while at home, the patient developed fever, headache, backache, and fatigue. After readmission to the 
hospital, the patient's mental status worsened from mild confusion with tremulousness to unresponsiveness; the 
patient subsequently died. Laboratory testing of his serum at a commercial facility was negative for West Nile 
virus infection. Testing of brain tissues obtained at autopsy showed extensive West Nile virus infection by 
immunohistochemical staining and quantitative PC R  (TaqMan).
Case 3 - A  female patient received a liver transplant on August 2, 2002. While hospitalized, the patient developed 
a low-grade fever, cough, and malaise one week following transplant. Her symptoms resolved and the patient was 
discharged home. Laboratory evaluation of her serum for West Nile virus is underway.
Case 4 - A  male patient received a heart transplant on August 2, 2002. The patient had been hospitalized for one 
month before transplant surgery. One week postoperatively, he developed ataxia followed by confusion, 
tremulousness, dysarthria, and obtundation. The patient required mechanical ventilation. West Nile virus IgM 
antibody testing of C SF and serum by MAC-ELISA at a Florida public health laboratory were strongly positive.
The patient's mental status is improving and he no longer requires mechanical ventilation.
Although the cause of these illnesses remains under investigation, this cluster of illnesses should alert clinicians 
to the possibility of West Nile virus infection in organ transplant recipients and in patients receiving blood 
transfusions. Very little is known about West Nile virus infection in organ transplant recipients. Three of the four 
organ recipients in this investigation developed encephalitis approximately 8-17 days following transplant surgery. 
Illness in the kidney transplant patients first presented as fever unresponsive to antimicrobial therapy followed by 
progressive deterioration in mental status, including ataxia, dysarthria, and tremulousness. All three required 
mechanical ventilation; one died from brainstem herniation. Despite extensive West Nile virus infection observed 
in brain tissue, initial West Nile virus serology on the deceased patient was reported as negative at a commercial 
reference laboratory.
The evidence to date indicates that virus was transmitted from donor to recipients through the transplanted 
organs. The organ donor may have acquired infection through a mosquito bite or from blood transfusions received 
before organ recovery. West Nile virus infection in organ transplant or blood transfusion recipients has not been 
previously reported and the risk for acquiring West Nile virus infection from donated organs or blood is not known. 
At present, data are insufficient to indicate any changes to existing organ or blood donor screening and testing 
practices. Public health officials have initiated precautionary measures including a recall of any remaining blood 
products from blood donors whose blood was given to the organ donor. An FDA alert regarding West Nile virus 
and blood safety can be found at http://www.fda.gov/cber/safety/westnile.htm. Questions for FDA may be directed 
to: 1-800-835-4709. This number has been set up to respond to both clinicians and the public.
The investigation into possible West Nile virus infection in organ transplant recipients is ongoing. Clinicians caring 
for patients with febrile illnesses, particularly those associated with unexplained meningitis or encephalitis, 
occurring in the weeks following organ transplant should consider West Nile virus infection as a possible cause of 
illness.
To help assess the possible risk of transmission of West Nile virus by blood transfusion, persons with probable or 
proven West Nile virus infection who donated blood one to two weeks before their illness began and could have 
been viremic at the time of donation as well as persons with unexplained meningitis or encephalitis which 
developed 3 to 21 days after receipt of a blood transfusion should be reported to local or state health 
departments. In addition, transfusion services and blood banks should follow usual FDA-required procedures for 
reporting any fatalities thought to be associated with a blood transfusion and investigating any non-fatal adverse 
events.
Organs and blood are lifesaving and in short supply. Donating blood is safe. For patients who need an organ 
transplant or blood transfusion, the benefits far outweigh any risks.
A  full description of the clinical features and diagnostic test options for West Nile virus infection can be found at 
http://www.cdc.gov/ncidod/dvbid/westnile/resources/fact_sheet_clinician.htm. West Nile virus infection can be 
diagnosed by detection of IgM antibody in cerebrospinal fluid or serum samples by MAC-ELISA. Clinicians who 
suspect West Nile virus infection can obtain rapid testing at state laboratories through state or local health 
departments.
The Centers for Disease Control and Prevention (CDC) protects people's health and safety by preventing and 
controlling diseases and injuries; enhances health decisions by providing credible information on critical health 
issues; and promotes healthy living through strong partnerships with local, national and international
organizations.
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